Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9304492 | 0.88 | TSHR (0.54) | MEN1KMT2ASPHK1EPHX2TSHR | |
| SCHEMBL106428 | 0.85 | SPHK1 (0.50) | MEN1KMT2ASPHK1EPHX2TSHR | |
| SCHEMBL106457 | 0.82 | ALDH1A1 (0.47) | KMT2AALDH1A1GAAFAAHHDAC1 | |
| SCHEMBL15947190 | 0.82 | TDP1 (0.48) | TP53LMNAALDH1A1MAPTNPSR1 | |
| SCHEMBL307975 | 0.81 | SPHK1 (0.55) | MEN1KMT2ASPHK1EPHX2TSHR | |
| SCHEMBL14817483 | 0.81 | NAPRT (0.53) | MEN1KMT2ASPHK1EPHX2TSHR | |
| SCHEMBL29051936 | 0.80 | SPHK1 (0.47) | MEN1KMT2ASPHK1EPHX2TSHR | |
| SCHEMBL17993520 | 0.80 | NAPRT (0.47) | MEN1KMT2ASPHK1EPHX2TSHR | |
| SCHEMBL10202156 | 0.80 | TSHR (0.48) | MEN1KMT2ASPHK1EPHX2TSHR | |
| SCHEMBL19026945 | 0.80 | SPHK1 (0.50) | MEN1KMT2ASPHK1EPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11298349-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220023284-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20210161885-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210154185-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20200108059-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-10543206-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190030021-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2019-01-31 | — | — | US | disclosed |
| CN-107778287-A | A kind of compound as tyrosine protein kinase inhibitor | 南昌弘益药业有限公司 | 2018-03-09 | — | — | CN | disclosed |
| US-9717720-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20140200242-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140194405-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2563362-B1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8637672-B2 | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130197230-A1 | METHODS OF PREPARING QUINOLINE DERIVATIVES | EXELIXIS, INC. | 2013-08-01 | — | — | US | disclosed |
| EP-2563362-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | Deciphera Pharmaceuticals, LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHAMACEUTICALS, LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2011137342-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200242-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 110/4885KMT2A 2377/4885SPHK1 3407/4885 |
| US-20140194405-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 3366/4885KMT2A 2562/4885SPHK1 3874/4885 |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 3366/4885KMT2A 2562/4885SPHK1 3874/4885 |
| US-20210154185-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 110/4885KMT2A 2377/4885SPHK1 3407/4885 |
| US-20200108059-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, HRH2 | MEN1 66/4885KMT2A 2091/4885SPHK1 2837/4885 |
| US-20190030021-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, HRH2 | MEN1 66/4885KMT2A 2091/4885SPHK1 2837/4885 |
| US-10543206-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | HAX1, HRH1, HRH2 | MEN1 66/4885KMT2A 2091/4885SPHK1 2837/4885 |
| US-11298349-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 110/4885KMT2A 2377/4885SPHK1 3407/4885 |
| US-20130197230-A1 | METHODS OF PREPARING QUINOLINE DERIVATIVES | F12, RECQL, H1-2 | MEN1 139/4885KMT2A 2566/4885SPHK1 1673/4885 |
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 110/4885KMT2A 2377/4885SPHK1 3407/4885 |
| US-20220023284-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 110/4885KMT2A 2377/4885SPHK1 3407/4885 |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 3366/4885KMT2A 2562/4885SPHK1 3874/4885 |
| US-20210161885-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 110/4885KMT2A 2377/4885SPHK1 3407/4885 |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 3366/4885KMT2A 2562/4885SPHK1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.